In the ever-evolving field of diabetes management, incretin mimetics have emerged as a glp-2 transformative therapeutic class. Among these, retaglutide, retatrutide, and trizepatide represent promising additions to the arsenal against type 2 diabetes. These medications function by mimicking the actions of natural GLP-1, a hormone that enhances insu